CELLULAR, MOLECULAR, HISTOPHATOL, AND PHYSIOL CHAR OF A MACAQUE MODEL OF COPD

COPD 猕猴模型的细胞、分子、组织磷脂和生理学特征

• 批准号: 8172629
• 负责人: DALLAS Melvin HYDE
• 金额: $ 7.6万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172629
• 关键词: Biological Markers; Chronic Obstructive Airway Disease; Computer Retrieval of Information on Scientific Projects Database; Development; Drug Delivery Systems; Funding; Grant; Institution; Macaca; Macaca mulatta; Modeling; Molecular; Monkeys; Research; Research Personnel; Resources; Respiratory Tract Infections; Source; Techniques; Time; Tissues; United States National Institutes of Health; Validation; Vascular Endothelial Growth Factors; clinically relevant; human disease; inhibitor/antagonist; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main aim of the study is to develop a rhesus monkey COPD model of human disease by treating two groups of monkeys: one group is exposed to DCS and a VEGF inhibitor, and the other group is exposed to clinically relevant levels of DCS and a respiratory infection. Treated COPD monkeys are compared to healthy controls. The above study should permit: 1. Characterization of the induction and subsequent development over time of the COPD response in rhesus monkeys. 2 Use of using cellular, molecular, and histopathological techniques, to confirm previous findings in human disease tissues (validation of model), as well as identify biomarkers and/or drug targets not previously associated with COPD.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该研究的主要目的是通过治疗两组猴子来开发人类疾病的恒河猴 COPD 模型：一组暴露于 DCS 和 VEGF 抑制剂，另一组暴露于临床相关水平的 DCS 和呼吸道疾病感染。 将接受治疗的慢性阻塞性肺病猴子与健康对照组进行比较。 上述研究应该允许： 1. 恒河猴 COPD 反应随时间的诱导和后续发展的特征。 2 使用细胞、分子和组织病理学技术来确认先前在人类疾病组织中的发现（模型验证），以及识别先前与 COPD 不相关的生物标志物和/或药物靶标。